|
Title
|
|
|
|
Docetaxel (taxotere(tm)), a novel taxoid, in the treatment of advanced colorectal-carcinoma - an eortc early clinical-trials group-study
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Docetaxel (Taxotere), a new semisynthetic taxoid, is a potentially important chemotherapeutic agent for the treatment of cancer. Forty patients with bidimensionally measurable advanced adenocarcinoma of the colon were treated with docetaxel 100 mg m(-2) every 3 weeks as a Ih infusion without routine premedication. Thirty-nine patients were eligible: 23 males and 16 females. Median age was 60 years (range 41-75) and WHO performance status 1 (0-2). Prior adjuvant chemotherapy was performed in four patients and prior radiotherapy in nine patients. Bidimensionally measurable disease sites included: liver in 26 patients, lymph nodes and abdominal/peritoneal masses in 13, lung/mediastinal masses in ten and subcutaneous nodes in four. The median number of cycles given was 2 (range 1-15). Thirty-three patients were evaluable for response. One patient (3%) achieved a complete response and two (6%) (95% confidence limits 0-14%) a partial response. Side-effects were similar to those observed in other studies. Docetaxel, given at this dosage and schedule, has minimal activity in the treatment of colorectal carcinoma. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
The British journal of cancer. - London
| |
|
Publication
|
|
|
|
London
:
1994
| |
|
ISSN
|
|
|
|
0007-0920
| |
|
DOI
|
|
|
|
10.1038/BJC.1994.309
| |
|
Volume/pages
|
|
|
|
70
:2
, p. 376-379
| |
|
ISI
|
|
|
|
A1994PA75300034
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|